Gastric cancer
Conditions
Interventions
Gold Standard:The effect of immunotherapy and chemotherapy by abdominal enhanced CT (according to RECIST V1.1 standard)
Index test:The 
of 
and 
by 
protein 
Sponsors
Department of General Surgery, The Chinese PLA General Hospital First Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinically and pathologically confirmed advanced gastric adenocarcinoma; 2. Aged 18-80 years; 3. According to AJCC/UICC 8: Preoperative clinical stage II to IV (CT2-4BN0-3M0-1); 4. Immunohistochemical results showed non-HER-2 positive; 5. ASA score <= III; 6. Informed consent of patients; 7. Eastern Cooperative tumor Group (ECOG) score 0-1; 8. Enough organ function can tolerate immunotherapy.
Exclusion criteria
Exclusion criteria: 1. Severe mental disorders; 2. Women who are pregnant or breastfeeding; 3. Patients with gastric stump cancer and other benign and malignant tumors; 4. Prior neoadjuvant or adjuvant chemoradiotherapy or immunotherapy was performed; 5. Immunohistochemistry showed positive HER-2; 6. Untreated peripheral neuropathy with CNS metastasis (> level 1); 7. Having or suspected of having an autoimmune disease; 8. Infectious diseases such as hepatitis B, hepatitis C, AIDS, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate after the second treatment period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate after fourth treatment period;Pathological complete response rate;3 year overall survival rate;3 year disease-free survival rate;Disease control rate;3 year progess-free survival rate; | — |
Countries
China
Contacts
Public ContactWei Bo
Department of General Surgery, The Chinese PLA General Hospital First Medical Center l
Outcome results
None listed